Mason W. Freeman graduated from Harvard College and received his M.D. at the University of California, San Francisco. He served as an intern, resident, endocrinology fellow, and Chief Resident in Medicine in the Department of Medicine at the Massachusetts General Hospital. He also trained as a post-doctoral research fellow in the Biology Department of the Massachusetts Institute of Technology and the Endocrine Unit at MGH where he contributed to the cloning of the first macrophage scavenger receptor to be molecularly identified as well as the parathyroid hormone receptor. He became Chief of the Lipid Metabolism Unit at the MGH in 1992 and continues to direct that Unit as well as the Translational Research Center at MGH. From 2005-2007, while on a leave of absence from Harvard, he served as a head of the Novartis Translational Medicine program for Cardiovascular & Metabolic Diseases as well as the company’s Global Head of Biomarker Development. For over a decade, Mason has served as a consultant to 5AM Ventures, a venture capital firm located in Boston and San Francisco that focuses on investing in start-up therapeutics companies, over forty of which have been created since he joined the firm in 2007. New FDA approved therapies in hyperkalemia and heart failure have resulted from programs to which Mason contributed development leadership. Dr. Freeman is a Professor of Medicine at Harvard Medical School and editor of the Adult Primary Care lipid section of one of the world’s most widely read and cited on-line medical textbooks, UpToDate.